scholarly journals Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types

2005 ◽  
Vol 58 (6) ◽  
pp. 621-625 ◽  
Author(s):  
J Malta-Vacas
Keyword(s):  
Gastric Cancer ◽  
Differential Expression ◽  
Release Factor ◽  
Histological Types

scholarly journals Differential Expression of the Epithelial-Mesenchymal Transition Regulators Snail, SIP1, and Twist in Gastric Cancer

2002 ◽  
Vol 161 (5) ◽  
pp. 1881-1891 ◽  
Author(s):  
Erika Rosivatz ◽  
Ingrid Becker ◽  
Katja Specht ◽  
Elena Fricke ◽  
Birgit Luber ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Differential Expression ◽  
Epithelial Mesenchymal Transition ◽  
Mesenchymal Transition

scholarly journals Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread

2009 ◽  
Vol 2 (4) ◽  
pp. 310-320 ◽  
Author(s):  
Konrad Franke ◽  
Stacy Carl-McGrath ◽  
Friedrich-Wilhelm Röhl ◽  
Uwe Lendeckel ◽  
Matthias P.A. Ebert ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Progression ◽  
Differential Expression ◽  
Intestinal Type ◽  
Nodal Spread

DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 431-431
Author(s):  
Hiroki Hara ◽  
Atsushi Takeno ◽  
Hisateru Yasui ◽  
Hiroshi Imamura ◽  
Hiroki Akamatsu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trials ◽  
Large Scale ◽  
Metastatic Gastric Cancer ◽  
Expression Level ◽  
Prospective Analysis ◽  
Limited Information ◽  
Her2 Expression ◽  
Histological Types ◽  
Expression Status

431 Background: FGFR2 and HER2 proteins are well-known molecular targets for cancer therapy, and there are emerging attractive protein-targeted agents such as second generation antibody-drug conjugates. However, there are still limited information about the expression status of FGFR2 and HER2 in gastrointestinal cancer and their relationship to patient background with cancer. In this study, expression status of FGFR2 and HER2 in advanced/metastatic gastric cancer (GC) and colorectal cancer (CRC) were prospectively analyzed in clinical setting. Moreover, eligible patients for the clinical trials of DS-1123 or DS-8201, which are FGFR2- or HER2-targeting anti-cancer agent respectively, were screened. Methods: Patients with advanced/metastatic GC, gastroesophageal junctional cancer (GEJ), and CRC were enrolled. Expression status of FGFR2 and HER2 were prospectively analyzed by IHC and/or FISH. Results: A total of 565 patients (GC; 160, GEJ; 16, CRC; 389) have been enrolled in this study from November 2016 to June 2018. FGFR2 expression (IHC 1+~3+) was observed in 24%, 44%, and 3% of GC, GEJ, and CRC respectively. HER2 expression (IHC 2+, 3+) was observed in 24%, 44%, and 17% of GC, GEJ, and CRC respectively. Expression levels of FGFR2 and HER2 seemed to be not correlated with each other in all 3 types of cancer. Distributions of expression level of FGFR2 or HER2 were slightly different among the histological types in GC. In CRC, distribution of HER2 expression level was also slightly different among the histological types and HER2 expression level was higher in KRAS/NRAS wild type compared to KRAS/NRAS mutant. There was no association between HER2 expression level and primary tumor sites in patients with CRC. Slight concordance of HER2 expression was observed between IHC and FISH in CRC. A total of 7 patients have been enrolled in clinical trials of DS-1123 or DS-8201 through this study based on the analysis findings. Conclusions: This study showed insights into the expression status of FGFR2 and HER2 in GC and CRC as a large-scale prospective analysis. Seven patients who had no standard therapy could access exploratory new drug based on targetable agents through this study. Clinical trial information: 163380.

Differential expression of motility-related protein-1 gene in gastric cancer and its premalignant lesions

2004 ◽  
Vol 1 (2) ◽  
pp. 111-115
Author(s):  
Yao Xu ◽  
Jie Zheng ◽  
Wentian Liu ◽  
Jun Xing ◽  
Yanyun Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Differential Expression ◽  
Premalignant Lesions ◽  
Related Protein

scholarly journals Differential expression profiles of long non-coding RNAs reveal potential biomarkers for identification of human gastric cancer

2015 ◽  
Vol 35 (3) ◽  
pp. 1529-1540 ◽  
Author(s):  
CHENGYUN LI ◽  
GEYU LIANG ◽  
WENZHUO YAO ◽  
JING SUI ◽  
XIAN SHEN ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Differential Expression ◽  
Expression Profiles ◽  
Human Gastric Cancer ◽  
Non Coding Rnas ◽  
Potential Biomarkers
Sign in / Sign up

Export Citation Format

Share Document